View More Recent Stories
-
Theralase(R) Closes Non-Brokered Private Placement
-
Theralase(R) Extends Warrants
-
Theralase(R) Provides Update on Bladder Cancer Clinical Study
-
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
-
Theralase(R) Extends Warrants
-
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
-
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
-
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
-
Theralase(R) Release’s 2Q2024 Financial Statements
-
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
-
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
-
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
-
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
-
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
-
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
-
Rutherrin(R) Increases Efficacy of Chemotherapy
-
Rutherrin(R) Increases Efficacy of Chemotherapy
-
Ruvidar(TM) Enhances Efficacy of Cancer Drug

